登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>EGFRvIII >EGI-HP2E3

PE-Labeled Human EGFRvIII Protein, His Tag (Site-specific conjugation)

分子别名(Synonym)

EGFRvIII

表达区间及表达系统(Source)

PE-Labeled Human EGFRvIII, His Tag (EGI-HP2E3) is produced via site-specific conjugation of PE to Human EGFRvIII (25-378), His Tag under optimal conditions with a proprietary technology. Human EGFRvIII, His Tag (EGI-HP2E3) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).

Predicted N-terminus: Leu 25

Request for sequence

蛋白结构(Molecular Characterization)

EGFRvIII Structure

This protein carries a polyhistidine tag at the C-terminus

The protein has a calculated MW of 42.2 kDa.

偶联(Conjugate)

PE

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

应用说明(Application)

Please note that this product is NOT compatible to streptavidin detection system.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

活性(Bioactivity)-FACS

EGFRvIII FACS

5e5 of anti-EGFRvIII CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human EGFRvIII Protein, His Tag (Cat. No. EGI-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

Protocol

 

背景(Background)

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
EGFRvIII靶点信息
英文全称:Epidermal growth factor receptor variant III
中文全称:表皮生长因子受体变体III
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:13详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定